FIL Ltd lowered its position in shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) by 56.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 181,009 shares of the company’s stock after selling 236,585 shares during the period. FIL Ltd owned about 0.70% of Verrica Pharmaceuticals worth $2,941,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Kornitzer Capital Management Inc. KS bought a new position in Verrica Pharmaceuticals during the second quarter valued at about $2,905,000. Dean Capital Investments Management LLC bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $676,000. Asymmetry Capital Management L.P. bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $1,184,000. FMR LLC bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $21,703,000. Finally, Fosun International Ltd bought a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $15,705,000. 30.86% of the stock is owned by institutional investors and hedge funds.
In other news, Director Paul B. Manning bought 70,200 shares of the firm’s stock in a transaction that occurred on Tuesday, November 13th. The shares were acquired at an average cost of $14.15 per share, with a total value of $993,330.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Linda Palczuk bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were purchased at an average cost of $16.52 per share, for a total transaction of $41,300.00. The disclosure for this purchase can be found here.
Verrica Pharmaceuticals stock opened at $12.00 on Monday. Verrica Pharmaceuticals Inc has a 52 week low of $11.10 and a 52 week high of $23.29.
Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts anticipate that Verrica Pharmaceuticals Inc will post -1.17 EPS for the current year.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.
Recommended Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.